Cellectis CLLS
NASDAQ CLLS
$1.43 +0.03 (+2.14%)
At close: Oct 2, 2026 · 4:00 PM EDT

Cellectis (CLLS) Return on Sales [ROS] (2015 - 2026)

Updated

Cellectis (CLLS) posted Return on Sales [ROS] of -449.82% for Q2 2026, down 392.50 percentage points from -57.32% a year earlier and down 14.18 percentage points from the prior quarter.

Analysis

Cellectis (CLLS) Return on Sales [ROS] (2015 - 2026) Analysis & Trends

For the trailing twelve months through Jun 30, 2026, Return on Sales [ROS] at Cellectis was -98.48%, down 18.17 percentage points year-over-year; for FY2025, it was -45.34%, up 98.15 percentage points from FY2024.

  • Annual Return on Sales [ROS] shows a five-year change of +143.05 percentage points (FY2020 to FY2025).
  • In prior years, Cellectis' Return on Sales [ROS] was -143.49% in FY2024 (+12744.20 pp), -12887.68% in FY2023 (-12419.97 pp), -467.72% in FY2022 (-126.72 pp) and -340.99% in FY2021 (-152.60 pp).
  • The Q2 2026 figure stands as the lowest quarterly Return on Sales [ROS] since Q1 2024.
  • On a year-over-year basis, Return on Sales [ROS] has declined in each of the last three quarters, with an average year-over-year change of +2933.00 percentage points over the last eight quarters.
  • The strongest year-over-year quarter for Return on Sales [ROS] in the past five years was Q1 2024, with a gain of 16395.39 percentage points; the weakest was Q3 2022, with a drop of 15120.56 percentage points.
  • According to Business Quant data, Return on Sales [ROS] for the three prior quarters was -435.64% (Q1 2026), -136.46% (Q4 2025) and 22.86% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn 51.16%
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn 28.21%
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn 37.86%
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn -3.52%
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn 32.97%
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn 20.57%
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn 34.95%
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn -133.21%
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn 28.37%
10 Cellectis 143.49 Mn -609.91 Mn - -449.82%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -449.82%
Mar 31, 2026 -435.64%
Dec 31, 2025 -136.46%
Sep 30, 2025 22.86%
Jun 30, 2025 -57.32%
Mar 31, 2025 -133.07%
Dec 31, 2024 -83.99%
Sep 30, 2024 -66.48%
Jun 30, 2024 -213.51%
Mar 31, 2024 -461.44%
Dec 31, 2023 -10,451.94%
Sep 30, 2023 -13,336.13%
Jun 30, 2023 -13,270.22%
Mar 31, 2023 -16,856.83%
Dec 31, 2022 -35.32%
Sep 30, 2022 -15,630.29%
Jun 30, 2022 -2,089.75%
Mar 31, 2022 -1,755.44%
Dec 31, 2021 -239.33%
Sep 30, 2021 -509.72%
API Access

Cellectis Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=CLLS&period=max&api_key=YOUR_API_KEY